• Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • Patients with an absence of cytotoxic T lymphocyte (CTL) function have a high risk for developing HLH, and could therefore benefit the most from early hematopoietic stem cell transplantation (HSCT). (biomedcentral.com)
  • NK cell allo-reactivity could also be utilized in additional scenarios besides hematopoietic stem cell transplantation (HSCT) with studies in malignant glioma and neuroblastoma individuals demonstrating that NK cell infusions are safe and partially effective (12, 13). (mycareerpeer.com)
  • Clinical Conditioning Not only chemotherapy and/or radiotherapy are required for the success of HSCT but also cellular immunotherapy. (mycareerpeer.com)
  • This was the first report of a hematopoietic stem cell transplantation (HSCT) conducted in Mexico, only 4 years after the pioneer work by E. Donnall Thomas in Cooperstown, New York, USA (Ruiz-Argüelles et al. (revistadehematologia.org.mx)
  • Hepatitis B virus (HBV) flare is a serious problem following hematopoietic stem cell transplantation (HSCT), and the mortality rate is high if severe hepatitis occurs. (springeropen.com)
  • Hepatitis B virus (HBV) flare and reactivation after hematopoietic stem cell transplantation (HSCT) is a life-threatening complication in patients with HBV infection (Liang et al. (springeropen.com)
  • 2009 ). The underlying mechanism of HBV flare and reactivation following HSCT is likely to be related to impaired cellular immunity caused by prior chemotherapy and conditioning regimens. (springeropen.com)
  • ABO blood group incompatibility is not a contraindication for allogeneic hematopoietic stem cell transplantation (allo-HSCT). (blood-genomics.com)
  • Isohemagglutinins (ISO) targeting red blood cell (RBC) antigens are associated with post-HSCT immunohematological complications, including hemolysis, passenger lymphocyte syndrome (PLS), and pure red cell aplasia (PRCA). (blood-genomics.com)
  • Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. (biomedcentral.com)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure, and is usually conducted to consolidate remission of haematological malignancies. (biomedcentral.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. (mayo.edu)
  • A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML (BMT CTN 1506) Rochester, Minn., Scottsdale/Phoenix, Ariz. (mayo.edu)
  • The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. (mayo.edu)
  • Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies? (haematologica.org)
  • Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. (sagepub.com)
  • As we continue to advance omidubicel for a potential launch and prepare to become a commercial organization, we are establishing key commercial capabilities, including the creation of Gamida Cell Assist a program designed to support a positive patient and transplant center experience. (seekingalpha.com)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • In April 1960, Dr. Álvaro Gómez-Leal, presented during the first meeting of the Agrupación Mexicana para el Estudio de la Hematología, A.C., data on a transplant of allogeneic stem cells in a patient with acute leukemia done in Monterrey, Mexico: the patient received high-dose chemotherapy followed by stem cells from the bone marrow of his brother, improving and obtaining remission for months but relapsing and subsequently died. (revistadehematologia.org.mx)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. (uchicago.edu)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • Clinical trials for stem cell and bone marrow transplant patients are an important tool for identifying new and more effective treatments for many diseases. (bmtinfonet.org)
  • And she's also an associated editor for the medical journal Bone Marrow Transplantation as well as a protocol officer and medical monitor for the National Heart Lung and Blood Institute, National Cancer Institute, Blood & Marrow Transplant Clinical Trials Network. (bmtinfonet.org)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
  • An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. (lookformedical.com)
  • Among 161 patients (pts) included in the study, with a median age of 53 years (17-72), 98 pts (60.9%) received a reduced-intensity conditioning (RIC), 36 pts (22.4%) reduced-toxicity conditioning (RTC), 18 pts (11.1 %) sequential conditioning, and 9 pts (5.6%) myeloablative conditioning (MAC). (confex.com)
  • Long haul resistant recuperation in more seasoned patients given hematopoietic cell transplantation after non-myeloablative molding remains ineffectively comprehended. (scitechnol.com)
  • As opposed to the aggravated circumstance in GVHD, when communication happens between enacted APC and benefactor T cells, the tissue harm brought about by myeloablative alloSCT brings about dermal enrollment of HLA class II-positive tissue fixing macrophages coinciding with expanded quantities of patient and contributor determined T cells, however without indications of explicit connection and commencement of a safe reaction. (scitechnol.com)
  • These patients got unmanipulated, myeloablative transfers utilizing either HLA indistinguishable or HLA jumbled, related or inconsequential contributor undeveloped cells. (scitechnol.com)
  • High risk of acute pulmonary toxicity with both myeloablative and non-myeloablative total body irradiation-based conditioning for allogeneic stem cell transplantation. (dukecancerinstitute.org)
  • Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
  • A total of 1,473 patients with a median age of 47 years received myeloablative conditioning, and 1,162 patients with a median age of 63 years received reduced-intensity conditioning. (ascopost.com)
  • About 328 patients received myeloablative conditioning, and 150 patients, reduced-intensity conditioning. (ascopost.com)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • 1. Definition: GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. (drcremers.com)
  • One to two days before your stem cell infusion, you'll take a regimen of drugs to help prevent GVHD. (drcremers.com)
  • Acute GVHD can occur soon after the transplanted cells begin to appear in the recipient. (drcremers.com)
  • RESULTS: The numbers of non-Japanese-to-Japanese and Japanese-to-non-Japanese BMT cases included in the analysis were 48 and 75, respectively, and the following outcomes were compared: overall survival, non-relapse mortality, acute graft-vs-host disease (GVHD) ≥ grade II, chronic GVHD, and engraftment of neutrophils and platelets. (bvsalud.org)
  • Reduced GvHD was hypothesized to be attributed to the lysis of the recipients antigen showing cells (APCs) reducing the incidence of GvHD while keeping GvL effect. (mycareerpeer.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
  • Acute GVHD occurs most frequently 30-40 days after engraftment. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • Recently, we established a regimen using low-dose PTCy in conjunction with standard-dose ATG in order to lower the risk of GVHD without compromising engraftment and disease relapse. (biomedcentral.com)
  • In this prospective trial, results indicated that low-dose PTCy is sufficient to lower acute GVHD in mouse model, partly due to the boosting of fast regulatory T cell (Treg) reconstitution. (biomedcentral.com)
  • In addition, low-dose PTCy could augment the protective effect of ATG on GVHD both in mouse and human sets while ensuring high rates of engraftment and keeping disease control [ 18 ]. (biomedcentral.com)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • 11 So far, no randomized trial had formally tested ATG after reduced intensity conditioning in transplants for a specific indication. (haematologica.org)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • The direct involvement of allo-reactive NK GSK1059865 cells in inducing anti-tumor effect in hematopoietic transplants was first shown in 2002 (8). (mycareerpeer.com)
  • At the time they performed the first transplants surprisingly little was known about hematopoietic stem cells, immune responses to transplants or the complex human leucocyte antigen system. (revistadehematologia.org.mx)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL Rochester, Minn., Jacksonville, Fla. (mayo.edu)
  • EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
  • This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. (mayo.edu)
  • Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia. (mayo.edu)
  • A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) Jacksonville, Fla., Rochester, Minn. (mayo.edu)
  • Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. (sagepub.com)
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. (sagepub.com)
  • An 18-year-old man underwent allogenic bone marrow transplantation (BMT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). (bvsalud.org)
  • Prompt Initiation of Conventional Chemotherapy to Avoid Early Death in Patients with Newly Diagnosed Acute Promyelocytic Leukemia. (u-tokyo-hemat.com)
  • This was later successfully translated into an model using acute myeloid leukemia (AML)-engrafted NOD/SCID mice infused with allo-reactive Rabbit Polyclonal to RPS6KB2 NK cells. (mycareerpeer.com)
  • Hematopoietic cell transplantation (HCT) is an integral part of the treatment of acute myeloid leukemia (AML). (apbmt.org)
  • Hematopoietic cell transplantation (HCT) is an effective treatment in patients with acute myeloid leukemia (AML). (apbmt.org)
  • Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. (uchicago.edu)
  • Identifying familial myelodysplastic/acute leukemia predisposition syndromes through hematopoietic stem cell transplantation donors with thrombocytopenia. (uchicago.edu)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. (kyoto-u.ac.jp)
  • Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy]. (kyoto-u.ac.jp)
  • The CD11b+ Kupffer cells producing TNF and FasL play a pivotal role in CCl4-induced acute hepatic injury thus. (enmd-2076.com)
  • Approximately one-third of children with acute myeloid leukemia (AML) experience disease relapse despite risk-adapted intensive multiagent chemotherapy with or without hematopoietic cell transplantation (HCT) [ 1 ]. (biomedcentral.com)
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
  • More specifically, the development of minimal intensity or so called "nonmyeloablative" conditioning regimens paved the way towards the application of allogeneic HCT in older patients and all of those who probably would not tolerate classical intensity conditioning. (haematologica.org)
  • Patients received a median of 3(range: 2-6) prior chemotherapy regimens (exclusive of tositumomab/iodine-131tositumomab) before or after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. (nature.com)
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • Bone Marrow Transplantation (2000) 25, 807-813. (nature.com)
  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (sagepub.com)
  • While both treatments help your bone marrow to develop new blood cells, studies show allogeneic stem cell transplantations work by causing the donor cells to attack unhealthy cells. (clevelandclinic.org)
  • The procedure of bone marrow / peripheral stem cell transplantation serves as a pivotal treatment avenue for patients contending with a spectrum of medical challenges. (medistateinternational.com)
  • While alternative therapeutic techniques persist, bone marrow/peripheral stem cell transplantation emerges as a transformative option, particularly when other methods display limited efficacy. (medistateinternational.com)
  • For conditions affecting the bone marrow-the essential hub for blood cell production-stem cell transplantation emerges as a potential avenue for patients grappling with insufficient or impaired blood production. (medistateinternational.com)
  • While some of these conditions show resistance to the benefits of bone marrow transplantation, others possess mild courses that don't necessitate transplantation. (medistateinternational.com)
  • This twofold approach not only harnesses the power of potent chemotherapy but also safeguards against bone marrow deficiency by replenishing the patient's stem cell count following the chemotherapy phase. (medistateinternational.com)
  • A 63-year-old man with adult T-cell leukemia-lymphoma underwent allogeneic bone marrow transplantation from an HLA-matched unrelated donor. (bvsalud.org)
  • However, after consolidation therapy, bone marrow aspiration performed to prepare for allogeneic hematopoietic stem cell transplantation revealed disease relapse. (bvsalud.org)
  • Subsequently, he underwent unrelated allogeneic bone marrow transplantation. (bvsalud.org)
  • METHODS: We used the Japanese National Database to examine the outcomes of first allogeneic bone marrow transplantations (BMTs) performed between Japanese and non-Japanese patients from 1996 to 2021. (bvsalud.org)
  • 2020 was an important year for Gamida Cell as we made significant progress across our entire pipeline, including omidubicel, which is poised to become the first FDA approved cell therapy for bone marrow transplantation. (seekingalpha.com)
  • Peripheral blood has largely replaced bone marrow as a source of stem cells, especially in autologous hematopoietic stem cell transplantation, because stem cell harvest is easier and neutrophil and platelet counts recover faster. (msdmanuals.com)
  • The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • The etiology of bone marrow failure (BMF) includes defective stem/progenitor cells and/or stroma/accessory cells/growth factors, as well as deficient nonspecific nutrients or, as in the case of acquired aplastic anemia, immune-mediated abnormalities. (medscape.com)
  • Inherited bone marrow failure syndromes (IBMFS) are usually the result of intrinsic stem cell/progenitor defects. (medscape.com)
  • Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. (scielo.org)
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
  • Extramedullary hematopoiesis (EMH) is likely the result of abnormal trafficking of hematopoietic stem cells (HSC) from the bone marrow to organs such as the spleen, liver, and lung, causing organomegaly and sometimes organ dysfunction. (cancernetwork.com)
  • The Allogeneic bone-marrow transplantation represents the only curative treatment and requires a compatible donor HLA. (longdom.org)
  • Bone marrow is the place for the production of the hematopoietic cells which differentiate in to three groups: red blood cells, white blood cells and platelets. (longdom.org)
  • Hematopoietic stem cells (HSCs) are very rare cells, representing approximately one in 100,000 bone marrow (BM) cells in the adult. (longdom.org)
  • Allogeneic bone marrow transplantation, as we understood it, allows saving lives, but cannot take place without donors. (longdom.org)
  • If the geno-identical transplantation is impossible, we will direct ourselves towards the national and international register donors of bone marrow. (longdom.org)
  • Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • Oddly enough, the serum MCP-1 Metoclopramide HCl level elevated and peaked at six h after c-lipo pretreatment quickly, suggesting which the MCP-1 made by c-lipo-phagocytized Compact disc68+ Kupffer cells Metoclopramide HCl may recruit Compact disc11b+ macrophages in the periphery and bone tissue marrow. (enmd-2076.com)
  • four othersreceived a reduced-intensity regimen consisting of fludarabine (Fludara),busulfan (Myleran), tacrolimus (Prograf), mycophenolate mofetil (CellCept), and4 Gy of total lymphoid radiation. (cancernetwork.com)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
  • We performed propensity score matching using sex, age group, underlying disease group, HLA mismatch, conditioning regimen intensity, and BMT implementation age to select Japanese-to-Japanese BMT patients as the controls. (bvsalud.org)
  • After undergoing an allogeneic haematopoietic stem cell transplantation (alloHCT), patients need intensive physiological and psychological rehabilitation. (mdpi.com)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
  • Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? (biomedcentral.com)
  • The American Society of Parenteral and Enteral Nutrition (ASPEN) and the French-speaking society of clinical nutrition and metabolism (SFNEP) recommend nutritional support during haematopoietic transplantation for patients who are malnourished or have decreased intake or decreased intestinal absorption over a prolonged period (grade B) [ 11 , 12 ]. (biomedcentral.com)
  • People in remission from AML may be candidates for allogeneic stem cell transplantation. (clevelandclinic.org)
  • This shown that NK cell infusions were feasible and safe and led to total remission in 5/19 individuals with poor prognosis AML (10). (mycareerpeer.com)
  • We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. (biomedcentral.com)
  • As primary endpoint, the event-free survival was compared to a cohort of 55 patients who completed chemotherapy and were in first complete remission but did not receive NK cells. (biomedcentral.com)
  • He underwent related haploidentical peripheral blood stem cell transplantation but died of relapse. (bvsalud.org)
  • However, Ph+ALL relapsed 4 months after the second BMT, and he received a haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) from his father. (bvsalud.org)
  • Additionally, the effectiveness of haploidentical NK cell therapy in the refractory disease was further improved by depleting sponsor regulatory T cells with IL-2 diphtheria toxin avoiding their immunosuppressive effect (11). (mycareerpeer.com)
  • The first evidence for the therapeutic effectiveness of natural killer (NK) cells in AML was established in a study of 57 adult patients, in which none of the 20 individuals who received haploidentical cell transplantation from a killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donor experienced disease relapse [ 2 ]. (biomedcentral.com)
  • NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (sagepub.com)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
  • In the last two decades allogeneic hematopoietic cell transplantation (HCT) has been used with increasing frequencies in hematologic malignancies with curative intent. (haematologica.org)
  • At Gamida Cell, we are at the forefront of developing and commercializing potentially curative medicines for patients by harnessing our proprietary NAM cell expansion technology. (seekingalpha.com)
  • Hematopoietic stem cell transplantation is the only potentially curative therapy, but it is only an option for select patients. (cancernetwork.com)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • This provoked us to examine long haul lymphocyte reconstitution and thymic work in 80 patients given allogeneic fringe blood foundational microorganisms after nonmyeloablative molding. (scitechnol.com)
  • The perception that late resistance in more established patients primarily relies upon mature T cells contained in the unite has significant ramifications since it proposes that drawn out safe capacity after HCT may be impacted by procedures of in vitro or in vivo T cell consumption of the join in these patients. (scitechnol.com)
  • In this review, a review examination was performed to survey the transfer result of grown up patients with ALL who had chimerism investigations of unfractionated BM cells or fringe blood subsets performed roughly 80 days after transplantation. (scitechnol.com)
  • Fragmented contributor engraftment was available just in the fringe blood T cells in a little level of patients. (scitechnol.com)
  • 3 After a wave of fascinating reports on the feasibility and efficacy of this "revolutionary" approach, some studies revealed that patients with a high risk of either disease recurrence or non-engraftment did not fare too well with this strategy. (haematologica.org)
  • Robin and coworkers now present the results of a retrospective analysis performed in patients with myelofibrosis receiving reduced intensity conditioning. (haematologica.org)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • All patients received high-dose etoposide (60 mg/kg) and allogeneic stem cell transplantation following the TBI. (nature.com)
  • Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. (sagepub.com)
  • The decision to proceed with transplantation hinges on a thorough assessment of patients' chances for successful results, along with a comprehensive understanding of therapy-related risks. (medistateinternational.com)
  • Shortly after conditioning, LPI levels were increased in 23 patients, with peak at day 0, returning to normal range upon engraftment in 21 patients. (karger.com)
  • In the majority of patients, this disorder is typically characterized by infantile-onset hemophagocytic lymphohistiocytosis (HLH), which is lethal unless allogeneic transplantation is performed. (biomedcentral.com)
  • Improved outcomes of transplantation have been reported when performed before the development of HLH, thus it is important to quickly differentiate patients that present with the childhood form of disease and to prematurely enroll them into a transplantation protocol. (biomedcentral.com)
  • Although AML is the most common indication for allogeneic HCT, the relatively small number of patients and the highly complex nature of the procedure often render prospective studies on HCT unfeasible. (apbmt.org)
  • 1,000 new AML patients undergoing allogeneic or autologous HCT. (apbmt.org)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Successful allogeneic transplantation of patients with suspected prior invasive mold infection. (uchicago.edu)
  • In fact, LAM treatments showed high resistance and recurrence rates in patients with chronic hepatitis B infection (CHB) undergoing liver transplantation (Perrillo et al. (springeropen.com)
  • One great advantage of MSC is that these cells may be directly obtained from individual patients, thereby eliminating the complications associated with immune rejection of allogenic tissue and infectious diseases. (biomedcentral.com)
  • Seventy-six percent of patients were treated with intensive chemotherapy. (scielo.org)
  • The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. (scielo.org)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • All patients but one in ATG cohort achieved myeloid engraftment by day 30 post-HCT. (biomedcentral.com)
  • Twenty-one patients (median age at diagnosis, 6.0 years [range, 0.1-15.3 years]) received a median of 12.5 × 10 6 NK cells/kg (range, 3.6-62.2 × 10 6 cells/kg) without major side effects. (biomedcentral.com)
  • This has led to the development of two therapeutic approaches to harness the antileukemic effect of alloreactive NK cells for patients with AML. (biomedcentral.com)
  • Patients may alternatively receive lympho-depleting chemotherapy followed by adoptive transfer of purified NK cells from an alloreactive donor, resulting in homeostatic lymphocyte proliferation with transient donor NK cell expansion in recipients [ 7 ]. (biomedcentral.com)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • Miller and colleagues later on translated NK cell therapy only into the medical center where allogeneic NK cells were infused into individuals with advanced malignancy alongside IL-2 administration. (mycareerpeer.com)
  • Several types of malignancy could therefore benefit from NK cell immunotherapy and current medical trials include pancreas, lungs, head/neck, breast, and renal cell carcinomas. (mycareerpeer.com)
  • Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)
  • We theorized that lower Treatment Related Mortality (TRM) with Reduced Intensity Conditioning (RIC) would bring about better Overall Survival (OS) contrasted and Myelo ablative Conditioning (MAC). (scitechnol.com)
  • The primary endpoint will assess the effect of EN on D100 mortality. (biomedcentral.com)
  • The proliferation and differentiation of pluripotent stem cells give rise to progeny that can populate the entire immunologic and hematopoietic systems through committed progenitors of both the lymphoid and myeloid lineages. (medscape.com)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • The increased understanding of immune tolerance and allogeneic antileukemic immune reactivity has led several investigators to develop optimized conditioning protocols and new strategies to manipulate the effector cells either within the graft or in vivo . (haematologica.org)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (sagepub.com)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (lookformedical.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • The median times for neutrophil and platelet engraftment were 13.5 and 12 days, respectively, and did not differ between the two cohorts. (nature.com)
  • only platelet engraftment was delayed in Japanese-to-non-Japanese BMT but not in non-Japanese-to-Japanese BMT. (bvsalud.org)
  • Contrasted with HLA indistinguishable matched kin giver and matched irrelevant benefactor grown up hematopoietic cell transplantation beneficiaries, quantitative lymphoid recuperation in UCB transplantation beneficiaries is more slow in the initial 3 months, however these distinctions vanished by months after transplantation. (scitechnol.com)
  • The primary endpoint of the study was time to neutrophil engraftment, or the time it took for the white blood cells to recover following transplantation. (seekingalpha.com)
  • A041501, A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Rochester, Minn. (mayo.edu)
  • And GDA-201, an innate natural killer cell or NK cell therapy. (seekingalpha.com)
  • An experienced multidisciplinary team in close consultation with the primary transplantation centre should perform the rehabilitation therapy. (mdpi.com)
  • Medical tests using autologous NK cells have shown the therapy to be nontoxic, however, they fail to show efficacy (7), which could become the result of inhibition by self-MHC-I. Allogeneic treatment therefore offers potential to offer an alternative therapy with improved effect. (mycareerpeer.com)
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
  • Transplantation and Cellular Therapy, Jul. (kyoto-u.ac.jp)
  • Transplantation and Cellular Therapy, Jun. (kyoto-u.ac.jp)
  • The lack of benefit may result from insufficient numbers and limited persistence of alloreactive donor NK cells but does not preclude its potential usefulness during other phases of therapy, or in combination with other immunotherapeutic agents. (biomedcentral.com)
  • If one of the brothers and sisters is compatible, we speak about geno-identical allogeneic transplantation having the advantage of reducing the complications post-transplantation. (longdom.org)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • This is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. (clevelandclinic.org)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • The mucosa-associated invariant T (MAIT) cells are innate-like T cells with restricted T cell receptor (TCR) usage, which are preferentially localized in mucosal tissues (liver, lung and gut) and respond to microbial infection by rapidly producing cytokines and cytotoxic effectors. (cryostem.org)